Knock-down of superoxide dismutase 1 sensitizes cisplatin-resistant human ovarian cancer cells

Jong Won Kim, Heather Sahm, Jinsam You, Mu Wang

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Background: Overexpression of superoxide dismutase 1 (SOD1) has been shown to be one of the factors involved in causing cisplatin resistance in ovarian cancer. Reduction of SOD1 expression is expected to restore, at least partially, cisplatin sensitivity in ovarian cancer chemotherapy. Here, we explored the potential of RNAi as a therapy for reversal of cisplatin resistance. Materials and Methods: SOD1-specific small-interfering RNA (siRNA) was synthesized and transfected into cisplatin-resistant cell line A2780/CP prior to treatment with 15 μM cisplatin. Cell survival was assessed by clonogenic assay. Results: An enhanced cisplatin sensitivity was observed in the A2780/CP cells treated with SOD1-specific siRNA, compared to non-siRNA-treated or scrambled-siRNA-treated control cells. Conclusion: Specifically targeting SOD1 could lead to sensitization of cisplatin-resistant ovarian cancer cells, and SOD1 may be used as a potential target for chemosensitizers.

Original languageEnglish
Pages (from-to)2577-2581
Number of pages5
JournalAnticancer Research
Volume30
Issue number7
StatePublished - Jul 2010

Fingerprint

Ovarian Neoplasms
Cisplatin
Small Interfering RNA
RNA Interference
Superoxide Dismutase-1
Cell Survival
RNA
Drug Therapy
Cell Line
Therapeutics

Keywords

  • Cisplatin
  • Drug resistance
  • Mass spectrometry
  • Ovarian cancer
  • Selected-reaction-monitoring
  • siRNA
  • Superoxide dismutase 1

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Knock-down of superoxide dismutase 1 sensitizes cisplatin-resistant human ovarian cancer cells. / Kim, Jong Won; Sahm, Heather; You, Jinsam; Wang, Mu.

In: Anticancer Research, Vol. 30, No. 7, 07.2010, p. 2577-2581.

Research output: Contribution to journalArticle

Kim, Jong Won ; Sahm, Heather ; You, Jinsam ; Wang, Mu. / Knock-down of superoxide dismutase 1 sensitizes cisplatin-resistant human ovarian cancer cells. In: Anticancer Research. 2010 ; Vol. 30, No. 7. pp. 2577-2581.
@article{60e187b4935949058e3cbcbbf5fbc36b,
title = "Knock-down of superoxide dismutase 1 sensitizes cisplatin-resistant human ovarian cancer cells",
abstract = "Background: Overexpression of superoxide dismutase 1 (SOD1) has been shown to be one of the factors involved in causing cisplatin resistance in ovarian cancer. Reduction of SOD1 expression is expected to restore, at least partially, cisplatin sensitivity in ovarian cancer chemotherapy. Here, we explored the potential of RNAi as a therapy for reversal of cisplatin resistance. Materials and Methods: SOD1-specific small-interfering RNA (siRNA) was synthesized and transfected into cisplatin-resistant cell line A2780/CP prior to treatment with 15 μM cisplatin. Cell survival was assessed by clonogenic assay. Results: An enhanced cisplatin sensitivity was observed in the A2780/CP cells treated with SOD1-specific siRNA, compared to non-siRNA-treated or scrambled-siRNA-treated control cells. Conclusion: Specifically targeting SOD1 could lead to sensitization of cisplatin-resistant ovarian cancer cells, and SOD1 may be used as a potential target for chemosensitizers.",
keywords = "Cisplatin, Drug resistance, Mass spectrometry, Ovarian cancer, Selected-reaction-monitoring, siRNA, Superoxide dismutase 1",
author = "Kim, {Jong Won} and Heather Sahm and Jinsam You and Mu Wang",
year = "2010",
month = "7",
language = "English",
volume = "30",
pages = "2577--2581",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "7",

}

TY - JOUR

T1 - Knock-down of superoxide dismutase 1 sensitizes cisplatin-resistant human ovarian cancer cells

AU - Kim, Jong Won

AU - Sahm, Heather

AU - You, Jinsam

AU - Wang, Mu

PY - 2010/7

Y1 - 2010/7

N2 - Background: Overexpression of superoxide dismutase 1 (SOD1) has been shown to be one of the factors involved in causing cisplatin resistance in ovarian cancer. Reduction of SOD1 expression is expected to restore, at least partially, cisplatin sensitivity in ovarian cancer chemotherapy. Here, we explored the potential of RNAi as a therapy for reversal of cisplatin resistance. Materials and Methods: SOD1-specific small-interfering RNA (siRNA) was synthesized and transfected into cisplatin-resistant cell line A2780/CP prior to treatment with 15 μM cisplatin. Cell survival was assessed by clonogenic assay. Results: An enhanced cisplatin sensitivity was observed in the A2780/CP cells treated with SOD1-specific siRNA, compared to non-siRNA-treated or scrambled-siRNA-treated control cells. Conclusion: Specifically targeting SOD1 could lead to sensitization of cisplatin-resistant ovarian cancer cells, and SOD1 may be used as a potential target for chemosensitizers.

AB - Background: Overexpression of superoxide dismutase 1 (SOD1) has been shown to be one of the factors involved in causing cisplatin resistance in ovarian cancer. Reduction of SOD1 expression is expected to restore, at least partially, cisplatin sensitivity in ovarian cancer chemotherapy. Here, we explored the potential of RNAi as a therapy for reversal of cisplatin resistance. Materials and Methods: SOD1-specific small-interfering RNA (siRNA) was synthesized and transfected into cisplatin-resistant cell line A2780/CP prior to treatment with 15 μM cisplatin. Cell survival was assessed by clonogenic assay. Results: An enhanced cisplatin sensitivity was observed in the A2780/CP cells treated with SOD1-specific siRNA, compared to non-siRNA-treated or scrambled-siRNA-treated control cells. Conclusion: Specifically targeting SOD1 could lead to sensitization of cisplatin-resistant ovarian cancer cells, and SOD1 may be used as a potential target for chemosensitizers.

KW - Cisplatin

KW - Drug resistance

KW - Mass spectrometry

KW - Ovarian cancer

KW - Selected-reaction-monitoring

KW - siRNA

KW - Superoxide dismutase 1

UR - http://www.scopus.com/inward/record.url?scp=77955820605&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955820605&partnerID=8YFLogxK

M3 - Article

VL - 30

SP - 2577

EP - 2581

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 7

ER -